Clinical Trial: Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07731789) titled 'Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma' on July 22.

Brief Summary: This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cance...